An aging society, greater incidence of diseases and disorders, and the extension of health insurance
coverage by the Affordable Care Act of 2010, will all spur US gains for IVD products.
US demand to approach
$25 billion in 2016
US demand for in vitro (IVD) diagnostic
products is forecast to rise 6.1 percent
annually to $24.7 billion in 2016. A
growing volume of patient care activity,
spurred by aging demographic patterns,
a heightened incidence of diseases and
disorders, and the extension of health
insurance coverage by the Affordable
Care Act of 2010, will underlie gains.
Advances in technology, along with
the introduction of new and improved
reagents and instruments, will drive up
demand in most IVD product segments.
Molecular diagnostic IVD
products to grow fastest
Demand for molecular diagnostic
products will grow the fastest among all
IVD products due to their throughput,
accuracy, and speed advantages in the
detection of infectious diseases, tumors,
and genetic disorders. The US market
for these products will benefit from the
introduction of new, high value-added
polymerase chain reaction (PCR) and
related tests to post double-digit gains
through 2016. Over the same period,
demand for blood testing reagents and
instruments will rise 3.4 percent per year
to $2.6 billion. Competition from new
immunoassay and molecular tests will
moderate growth in demand.
Uses in patient health screening and
diabetes self-monitoring, coupled with
the widening availability of integrated
and point-of-care systems offering
greater productivity and operating ease,
will boost demand for clinical chemistry
products. The expansion of test menus
for therapeutic drug monitoring, infectious
disease detection, and cardiovascular
and cancer testing, along with
advances in chemiluminescent and other
advanced systems, will promote gains
for immunoassay products. Companion
diagnostics used to determine the safety
and effectiveness of drug therapies will
provide especially strong growth for
these products.
Cellular analysis reagents and instruments
will continue to generate sizable
demand from uses in ovarian and breast
cancer screening and HIV monitoring.
By contrast, demand for anatomical
pathology reagents and instruments will
expand well above the overall average
growth pace of IVD products as clinical
and forensic laboratories upgrade testing
capabilities. The market for microbiology
products will rise at a comparatively slow
pace as molecular diagnostic and
immunoassay technologies penetrate
cancer and infectious disease testing
procedures.
Hospital laboratories to
remain dominant market
Hospital laboratories will continue to be
the largest and most diverse market for
IVD products based on extensive
inpatient, emergency, and post-surgical
testing activities. The home health care
segment will expand at the fastest pace,
with the vast majority of demand remaining
concentrated in diabetes monitoring
products. Through upgrading and
broadening testing capabilities, independent
clinical laboratories will continue to
form the second largest overall and
second fastest growing market served
by the IVD industry.
Study Scope
This study analyzes the $18.4 billion US IVD products industry, with forecasts for 2016 and 2021 by product type (e.g., clinical chemistry, immunoassay, molecular diagnostic, blood testing, cellular analysis, anatomical pathology, microbiology), application (e.g., infectious disease testing, cancer testing, diabetes testing, heart disease testing, blood grouping and screening, drug testing) and market (e.g., hospitals, independent clinical laboratories).
The study also considers market environment factors, details industry structure, evaluates company market share and profiles 27 industry players, including Roche, Johnson & Johnson and Danahar.
